CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 107 filers reported holding CLOVIS ONCOLOGY INC in Q2 2013. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $1,329,000 | -98.4% | 1,117 | -97.6% | 0.00% | – |
Q2 2022 | $83,808,000 | +419.8% | 46,560 | +483.3% | 0.00% | – |
Q1 2022 | $16,124,000 | -73.0% | 7,982 | -63.7% | 0.00% | – |
Q4 2021 | $59,609,000 | -32.2% | 21,996 | +11.6% | 0.00% | – |
Q3 2021 | $87,902,000 | +322.6% | 19,709 | +449.6% | 0.00% | – |
Q2 2021 | $20,799,000 | -70.7% | 3,586 | -64.6% | 0.00% | – |
Q1 2021 | $71,077,000 | -64.9% | 10,125 | -76.0% | 0.00% | – |
Q4 2020 | $202,272,000 | +15.6% | 42,140 | +40.4% | 0.00% | – |
Q3 2020 | $174,970,000 | -90.8% | 30,012 | -89.4% | 0.00% | -100.0% |
Q2 2020 | $1,903,378,000 | +2.8% | 281,982 | -3.1% | 0.00% | -25.0% |
Q1 2020 | $1,850,715,000 | +127.7% | 290,993 | +287.9% | 0.00% | +300.0% |
Q4 2019 | $812,941,000 | +179.7% | 75,010 | +5.7% | 0.00% | – |
Q3 2019 | $290,667,000 | -51.1% | 70,991 | +91.8% | 0.00% | -100.0% |
Q2 2019 | $594,503,000 | -52.5% | 37,010 | -22.0% | 0.00% | -66.7% |
Q1 2019 | $1,251,747,000 | +80.6% | 47,463 | +192.5% | 0.00% | +50.0% |
Q4 2018 | $693,220,000 | -50.4% | 16,224 | -6.0% | 0.00% | 0.0% |
Q3 2018 | $1,396,867,000 | -28.4% | 17,267 | +37.0% | 0.00% | -50.0% |
Q2 2018 | $1,950,527,000 | -8.6% | 12,603 | -68.8% | 0.00% | 0.0% |
Q1 2018 | $2,134,440,000 | +245.2% | 40,425 | +344.6% | 0.00% | +300.0% |
Q4 2017 | $618,324,000 | +44.4% | 9,093 | +74.9% | 0.00% | 0.0% |
Q3 2017 | $428,315,000 | -12.9% | 5,198 | -1.0% | 0.00% | 0.0% |
Q2 2017 | $491,557,000 | +860.2% | 5,250 | +553.0% | 0.00% | – |
Q1 2017 | $51,191,000 | -49.4% | 804 | -64.7% | 0.00% | – |
Q4 2016 | $101,100,000 | +6.3% | 2,276 | -13.8% | 0.00% | – |
Q3 2016 | $95,136,000 | +461.9% | 2,639 | +113.9% | 0.00% | – |
Q2 2016 | $16,930,000 | -92.8% | 1,234 | -81.7% | 0.00% | -100.0% |
Q4 2015 | $235,410,000 | -54.1% | 6,726 | +20.7% | 0.00% | 0.0% |
Q3 2015 | $512,401,000 | +181.8% | 5,572 | +169.3% | 0.00% | 0.0% |
Q2 2015 | $181,824,000 | +318.0% | 2,069 | +253.1% | 0.00% | – |
Q1 2015 | $43,499,000 | -34.1% | 586 | -59.7% | 0.00% | – |
Q3 2014 | $65,999,000 | +378.2% | 1,455 | +535.4% | 0.00% | – |
Q4 2013 | $13,802,000 | -94.5% | 229 | -94.4% | 0.00% | – |
Q3 2013 | $248,915,000 | -24.7% | 4,094 | -17.1% | 0.00% | – |
Q2 2013 | $330,613,000 | – | 4,936 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 814,833 | $45,630,648,000 | 43.63% |
EcoR1 Capital, LLC | 384,348 | $21,523,000 | 10.89% |
Palo Alto Investors LP | 2,102,857 | $117,760,000 | 6.91% |
NEA Management Company, LLC | 2,279,781 | $127,668,000 | 6.19% |
Redmile Group, LLC | 721,632 | $40,411,000 | 4.40% |
Opaleye Management Inc. | 140,000 | $7,840,000 | 3.96% |
CLIFTON PARK CAPITAL MANAGEMENT, LLC | 790,555 | $44,271,000 | 2.63% |
SUFFOLK CAPITAL MANAGEMENT LLC | 339,327 | $19,002,000 | 2.31% |
PFM Health Sciences, LP | 1,725,126 | $96,607,000 | 2.26% |
HARBOURVEST PARTNERS LLC | 51,037 | $2,858,000 | 1.50% |